ZCM
TVTX icon

Zebra Capital Management’s Travere Therapeutics TVTX Stock Holding History

Zebra Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,545
Closed -$154K – 216
2021
Q2 		$154K Sell
10,545
-1,139
-10% -$22.5K 0.18% 143
2021
Q1 		$292K Sell
11,684
-32,328
-73% -$893K 0.32% 114
2020
Q4 		$1.2M Buy
44,012
+4,212
+11% +$98.3K 1.52% 6
2020
Q3 		$735K Buy
39,800
+25,825
+185% +$502K 1.14% 16
2020
Q2 		$285K Buy
13,975
+378
+3% +$6.02K 0.41% 98
2020
Q1 		$198K Sell
13,597
-974
-7% -$14.7K 0.32% 143
2019
Q4 		$207K Buy
14,571
+4,011
+38% +$51.2K 0.18% 230
2019
Q3 		$122K Buy
+10,560
New +$175K 0.13% 206

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Zebra Capital Management's TVTX Position: Q3 2021 in Review

Zebra Capital Management sold out of Travere Therapeutics (TVTX) in Q3 2021, closing a stake of 10,545 shares — an estimated $154K sold.

Zebra Capital Management first reported a position in TVTX in Q3 2019 and held it in 8 quarters. The position peaked at $1.2M in Q4 2020. 148 funds tracked by Wall St. Rank hold TVTX as of Q3 2021.

  • Zebra Capital Management reported no remaining Travere Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Zebra Capital Management sold 10,545 Travere Therapeutics shares in Q3 2021, an estimated $154K.
  • Zebra Capital Management first reported a position in Travere Therapeutics in Q3 2019 and held it in 8 quarters.
  • Zebra Capital Management's Travere Therapeutics position peaked at $1.2M in Q4 2020.
  • 148 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2021.

Based on Zebra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.